Trial Profile
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Feb 2023
Price :
$35
*
At a glance
- Drugs SER 262 (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Seres Therapeutics
- 02 Feb 2023 Status changed from active, no longer recruiting to completed.
- 18 Apr 2018 Planned End Date changed from 1 Jun 2017 to 1 Oct 2018.
- 18 Apr 2018 Planned primary completion date changed from 1 Apr 2017 to 1 Jun 2018.